13
Participants
Start Date
September 30, 2011
Primary Completion Date
July 31, 2014
Study Completion Date
November 30, 2014
recMAGE-A3 Protein + AS15 Adjuvant
recMAGE-A3 + AS15 was administered intramuscularly at a dose of 300 µg recMAGE-A3, with no dose adjustments permitted. The first immunization was administered 6 to 15 week prior to auto-SCT, with subsequent immunizations administered on Days 10, 31, 52, 73, and 94 (± 3 days) and Days 180 and 270 (± 7 days) after auto-SCT.
New York University School of Medicine, New York
Mount Sinai Hospital, New York
Memorial Sloan-Kettering Cancer Center, New York
Fox Chase Cancer Center, Philadelphia
Lead Sponsor
Collaborators (1)
GlaxoSmithKline
INDUSTRY
MOUNT SINAI HOSPITAL
OTHER
NYU Langone Health
OTHER
Fox Chase Cancer Center
OTHER
Memorial Sloan Kettering Cancer Center
OTHER
Ludwig Institute for Cancer Research
OTHER